RJFSA
SPRY icon

Raymond James Financial Services Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Raymond James Financial Services Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.14M Buy
78,779
+68,329
+654% +$813K ﹤0.01% 2082
2024
Q2 		$88.9K Buy
+10,450
New +$92.7K ﹤0.01% 3252
2023
Q1 		– Sell
-16,742
Closed -$143K – 3395
2022
Q4 		$143K Buy
+16,742
New +$109K ﹤0.01% 2948

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Raymond James Financial Services Advisors's SPRY Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its ARS Pharmaceuticals (SPRY) stake by 654% in Q3 2024, buying an estimated $813K and bringing the position to 78,779 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2082.

Raymond James Financial Services Advisors first reported a position in SPRY in Q4 2022 and has held it in 3 quarters since. 151 funds tracked by Wall St. Rank hold SPRY as of Q3 2024.

  • Raymond James Financial Services Advisors held 78,779 shares of ARS Pharmaceuticals worth $1.14M as of Q3 2024.
  • Raymond James Financial Services Advisors bought 68,329 ARS Pharmaceuticals shares in Q3 2024, an estimated $813K.
  • ARS Pharmaceuticals made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2082 holding.
  • Raymond James Financial Services Advisors first reported a position in ARS Pharmaceuticals in Q4 2022 and has held it in 3 quarters since.
  • 151 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.